ICER Sets Ceiling For Anti-Amyloid Pricing; Will Eisai And Lilly Raise The Roof?
US FDA Approvals For Both Firms’ Antibodies Expected Early 2023
The independent drug pricing watchdog said lecanemab and donanemab would be cost-effective at $8,500-$20,600 per year, but pricing has been expected to be closer to Aduhelm’s $28,200 price tag.
